BioNexus Gene Lab Corp. Accounts Payable
BioNexus Gene Lab Corp. (BGLC) had Accounts Payable of $1.18 million as of 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2025-05-15
- 2025-03-31: Accounts Payable, Current $1.18M.
- 2024-12-31: Accounts Payable, Current $1.50M.
- 2024-09-30: Accounts Payable, Current $1.03M.
- 2024-06-30: Accounts Payable, Current $954.78K.
| Period end | Accounts Payable, Current |
|---|---|
| 2025-03-31 | $1.18M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $1.50M 10-Q · filed 2025-05-15 |
| 2024-09-30 | $1.03M 10-Q · filed 2024-11-15 |
| 2024-06-30 | $954.78K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $1.43M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $1.40M 10-K · filed 2025-04-15 |
| 2023-09-30 | $1.57M 10-Q/A · filed 2024-03-26 |
| 2023-06-30 | $1.82M 10-Q · filed 2023-08-16 |
| 2023-03-31 | $1.49M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.86M 10-K · filed 2024-04-16 |
| 2022-09-30 | $1.28M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.42M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $1.83M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $2.01M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |